Synthesis of novel pyridine‐4‐hydrazide derivatives demonstrated potent antitubercular activity against MDR strains, suggesting new treatment avenues.
Key Points
Compounds exhibited potent inhibition against Mtb H 37 Rv, with minimum inhibitory concentrations between 0.125 and 2 µg/mL.
Lead candidates showed strong activity against multidrug-resistant clinical isolates and excellent safety profiles with selectivity indices of 400 to 800.
In silico studies using molecular docking and 3D‐QSAR correlated structural features with experimental antitubercular activity.
These findings highlight the potential of synthesized derivatives as next‐generation anti‐TB agents, warranting further investigation.